Label: SODIUM CHLORIDE injection, solution

  • NDC Code(s): 46066-512-04, 46066-512-05, 46066-512-06
  • Packager: ASPEN VETERINARY
  • Category: PRESCRIPTION ANIMAL DRUG LABEL
  • DEA Schedule: None
  • Marketing Status: unapproved drug other

DISCLAIMER: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here.

Drug Label Information

Updated December 15, 2017

If you are a consumer or patient please visit this version.

  • WARNINGS AND PRECAUTIONS

    STERILE NONPYROGENIC SOLUTION
    For Animal Use Only

  • Description

    Sodium Chloride 0.9% Injection is a sterile, non-pyrogenic solution intended for water and electrolytes replenishment in single dose containers. May be administered intravenously using aseptic technique. It contains no antimicrobial agents. Discard any unused portion. Composition, osmolarity, pH and ionic concentration are shown in Table 1.

    Table 1

    Table1

    The container is free of PVC and phthalates. The container meets the requirements of USP and is registered with FDA.

  • Clinical Pharmacology

    Sodium Chloride 0.9% Injection is intended to restore water and electrolytes. It is capable of inducing diuresis, depending on the clinical condition of the patient.

  • Indications

    Sodium Chloride 0.9% Injection is indicated as a source of water and electrolytes.

  • Contraindications

    None known.

  • Warnings

    Sodium Chloride 0.9% Injection should be used with great care, if at all, in patients with congestive heart failure, severe renal insufficiency, and in clinical states in which there exists edema with sodium retention.

    The intravenous administration of Sodium Chloride 0.9% Injection can cause fluid and/or solute overloading resulting in dilution of serum electrolyte concentrations, over-hydration, congested states, or pulmonary edema. The risk of dilutive states is inversely proportional to the electrolyte concentration of the injections. The risk of solute overload causing congested states with peripheral and pulmonary edema is directly proportional to the electrolyte concentrations of the injections.

    In patients with diminished renal function, administration of Sodium Chloride 0.9% Injection may result in sodium retention.

  • Adverse Reactions

    Reactions which may occur because of the solution or the technique of administration include febrile response, infection at the site of injection, venous thrombosis or phlebitis extending from the site of injection, extravasation, and hypervolemia.

    If an adverse reaction does occur, discontinue the infusion, evaluate the patient, institute appropriate therapeutic countermeasures and save the remainder of the fluid for examination if deemed necessary.

  • Precautions

    This is a single dose unit. It contains no preservatives. Use entire contents when first opened.

    Clinical evaluation and periodic laboratory determinations are necessary to monitor changes in fluid balance, electrolyte concentrations, and acid base balance during prolonged parenteral therapy or whenever the condition of the patient warrants such evaluation.

    Caution must be exercised in the administration of Sodium Chloride 0.9% Injection to patients receiving corticosteroids or corticotrophin.
    Do not administer unless solution is clear and seal is intact.

    Solution must be warmed to body temperature prior to administration at a slow rate. Use solution promptly following initial entry.

    Reactions which may occur because of the solution or the technique of administration, include febrile response, infection at the site of injection, extravasation, and hypervolemia.

  • Dosage and Administration

    As directed by a veterinarian. Dosage is dependent upon the age, weight and clinical condition of the patient, as well as laboratory determinations.

    Parenteral drug products should be inspected visually for particulate matter and discolouration prior to administration whenever solution and container permit.

    Additives may be incompatible. Complete information is not available. Those additives known to be incompatible should not be used. Mix thoroughly when additives have been introduced. Do not store solutions containing additives.

  • Over-dosage

    In an event of over-hydration or solute overload, re-evaluate the patient and institute appropriate corrective measures. See Warnings, Precautions and Adverse Reactions.

  • Storage

    Exposure of pharmaceutical products to heat should be minimized. Avoid excessive heat. It is recommended the product be stored at room temperature (86°F/30°C). Protect from freezing.

  • Directions for use of plastic container

    To Open

    Tear overwrap at slit and remove solution container. Some opacity of the plastic due to moisture absorption during the sterilization process may be observed. This is normal and does not affect the solution quality or safety. The opacity will diminish gradually. Check for minute leaks by squeezing solution container firmly. If leaks are found, discard solution as sterility may be impaired. If supplemental medication is desired, follow directions below:

    Preparation for Administration

    1. Suspend container from eyelet support.
    2. Remove plastic protector from inlet/outlet port at bottom of container.
    3. Attach administration set.

    To Add Medication

    WARNING: Additives may be incompatible.
    To add medication before solution administration

    1. Prepare medication site.
    2. Using syringe with 0.63mm to 0.80mm needle, puncture medication port and inject.
    3. Mix solution and medication thoroughly. For high density medication such as potassium chloride, squeeze ports while ports are upright and mix thoroughly.

    To add medication during solution administration

    1. Close the clamp on the administration set.
    2. Prepare medication site.
    3. Using syringe with 0.63mm to 0.80mm needle, puncture medication port and inject.
    4. Remove container from IV pole and/or turn to an upright position.
    5. Evacuate both ports by squeezing them while container is in the upright position.
    6. Mix solution and medication thoroughly.
    7. Return container to in use position and continue administration.

  • WARNINGS AND PRECAUTIONS

    CAUTION: FEDERAL LAW RESTRICTS THIS DRUG TO USE BY OR ON THE ORDER OF A LICENSED VETERINARIAN.

  • INFORMATION FOR OWNERS/CAREGIVERS

    Manufactured for:
    Aspen Veterinary Resources® Ltd.
    Liberty, MO 64068, USA
    www.aspenveterinaryresources.com

    Manufactured by:
    Sypharma Pty Ltd
    27 Healey Road, Dandenong
    Victoria 3175 Australia

    For customer service email:
    info@aspenveterinaryresources.com

    Rev. 04/16

  • Sodium Chloride 0.9% Injection 250mL

    SC250mL

  • Sodium Chloride 0.9% Injection 500mL

    SC500mL

  • Sodium Chloride 0.9% Injection 1000mL

    SC1000mL

  • INGREDIENTS AND APPEARANCE
    SODIUM CHLORIDE 
    sodium chloride injection, solution
    Product Information
    Product TypePRESCRIPTION ANIMAL DRUGItem Code (Source)NDC:46066-512
    Route of AdministrationINTRAVENOUS
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    SODIUM CHLORIDE (UNII: 451W47IQ8X) (SODIUM CATION - UNII:LYR4M0NH37, CHLORIDE ION - UNII:Q32ZN48698) SODIUM CHLORIDE900 mg  in 100 mL
    Inactive Ingredients
    Ingredient NameStrength
    WATER (UNII: 059QF0KO0R)  
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC:46066-512-0436 in 1 CASE
    1250 mL in 1 CONTAINER
    2NDC:46066-512-0524 in 1 CASE
    2500 mL in 1 CONTAINER
    3NDC:46066-512-0612 in 1 CASE
    31000 mL in 1 CONTAINER
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    unapproved drug other05/25/2016
    Labeler - ASPEN VETERINARY (627265361)
    Registrant - SYPHARMA PTY LTD (753786292)
    Establishment
    NameAddressID/FEIBusiness Operations
    SYPHARMA PTY LTD753786292manufacture, pack, sterilize